Advertisement
As of 02:52PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 5.57 |
| Open | 5.52 |
| Bid | 5.74 x 1800 |
| Ask | 5.75 x 1400 |
| Day's Range | 5.47 - 5.85 |
| 52 Week Range | 5.30 - 18.55 |
| Volume | |
| Avg. Volume | 8,625,622 |
| Market Cap | 683.063M |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.60 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Novavax, Inc.Daily – Vickers Top Buyers & Sellers for 04/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
Motley FoolIs Novavax Stock a Buy Now?
Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece.
Moneywise‘Nobody wants to speak about COVID’: Less than 3% of eligible Americans got a booster shot in September — does that mean trouble for these 3 big vaccine stocks?
Market performance hangs on U.S. vaccination rates for these three companies.
ZacksNovavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.